BACKGROUND: Involved field radiation therapy (IFRT) is integral in curative therapy for Hodgkin lymphoma (HL), although primarily used in patients with intermediate/high-risk HL. We present failure patterns and clinical outcomes in a cohort of pediatric and young adult patients with HL treated with IFRT at the Johns Hopkins Hospital. PROCEDURE: Patients ≤40 years old with intermediate/high-risk HL who received chemotherapy and IFRT from 1997 to 2012 were included in this retrospective analysis. Patients were evaluated for failure patterns, overall survival (OS), and event-free survival (EFS) using Kaplan-Meier curves, descriptive statistics, and Cox proportional hazard regressions. RESULTS: We reviewed 74 patients (45 pediatric and 29 young adult) with a median follow-up of 4.4 years. The mean age at diagnosis was 21.4 years. Patients received a median of 29.75 Gy of IFRT (range 15-39.6 Gy). The majority of pediatric patients received ABVE-PC chemotherapy (n = 25) and <30 Gy of radiation (n = 33) while most young adults received ABVD chemotherapy (n = 24) and ≥30 Gy (n = 25). Estimated 5-year OS and EFS were 96% and 81%, respectively. Thirteen patients had recurrence; eight were pediatric. Distant relapse alone comprised 83% of failures in patients receiving ≥30 Gy. Of the seven patients who received <30 Gy and had recurrence, six had local failure as a component of their recurrence. Caucasian race (P = 0.02) and nodular sclerosing histology (P = 0.01) predicted for increased EFS. Late effects were minimal and all deaths (n = 4) were from HL. CONCLUSIONS: In this series, pediatric and young adult patients were treated with differing chemoradiation and had distinct recurrence patterns.
BACKGROUND: Involved field radiation therapy (IFRT) is integral in curative therapy for Hodgkin lymphoma (HL), although primarily used in patients with intermediate/high-risk HL. We present failure patterns and clinical outcomes in a cohort of pediatric and young adult patients with HL treated with IFRT at the Johns Hopkins Hospital. PROCEDURE: Patients ≤40 years old with intermediate/high-risk HL who received chemotherapy and IFRT from 1997 to 2012 were included in this retrospective analysis. Patients were evaluated for failure patterns, overall survival (OS), and event-free survival (EFS) using Kaplan-Meier curves, descriptive statistics, and Cox proportional hazard regressions. RESULTS: We reviewed 74 patients (45 pediatric and 29 young adult) with a median follow-up of 4.4 years. The mean age at diagnosis was 21.4 years. Patients received a median of 29.75 Gy of IFRT (range 15-39.6 Gy). The majority of pediatric patients received ABVE-PC chemotherapy (n = 25) and <30 Gy of radiation (n = 33) while most young adults received ABVD chemotherapy (n = 24) and ≥30 Gy (n = 25). Estimated 5-year OS and EFS were 96% and 81%, respectively. Thirteen patients had recurrence; eight were pediatric. Distant relapse alone comprised 83% of failures in patients receiving ≥30 Gy. Of the seven patients who received <30 Gy and had recurrence, six had local failure as a component of their recurrence. Caucasian race (P = 0.02) and nodular sclerosing histology (P = 0.01) predicted for increased EFS. Late effects were minimal and all deaths (n = 4) were from HL. CONCLUSIONS: In this series, pediatric and young adult patients were treated with differing chemoradiation and had distinct recurrence patterns.
Authors: Mark S Pearce; Louise Parker; Kevin P Windebank; Simon J Cotterill; Alan W Craft Journal: Pediatr Blood Cancer Date: 2005-10-15 Impact factor: 3.167
Authors: Lena Specht; Joachim Yahalom; Tim Illidge; Anne Kiil Berthelsen; Louis S Constine; Hans Theodor Eich; Theodore Girinsky; Richard T Hoppe; Peter Mauch; N George Mikhaeel; Andrea Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-06-18 Impact factor: 7.038
Authors: N P Mendenhall; L L Rodrigue; G J Moore-Higgs; R B Marcus; R R Million Journal: Int J Radiat Oncol Biol Phys Date: 1999-06-01 Impact factor: 7.038
Authors: James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: O Oberlin; G Leverger; H Pacquement; M A Raquin; A Chompret; J L Habrand; M J Terrier-Lacombe; P Bey; Y Bertrand; H Rubie Journal: J Clin Oncol Date: 1992-10 Impact factor: 44.544
Authors: M M Hudson; C Greenwald; E Thompson; J Wilimas; N Marina; D Fairclough; W Kauffman; P Bozeman; P W Mackert; M Abromowitch Journal: J Clin Oncol Date: 1993-01 Impact factor: 44.544
Authors: James E Bates; Stephanie Terezakis; Christopher G Morris; Avani D Rao; Shuchi Sehgal; Rahul Kumar; Raymond B Mailhot Vega; Nancy P Mendenhall; Bradford S Hoppe Journal: Int J Part Ther Date: 2021-07-08
Authors: Matthew D Hall; Stephanie A Terezakis; John T Lucas; Eve Gallop-Evans; Karin Dieckmann; Louis S Constine; David Hodgson; Jamie E Flerlage; Monika L Metzger; Bradford S Hoppe Journal: Int J Radiat Oncol Biol Phys Date: 2021-08-12 Impact factor: 7.038